HCW Biologics Inc.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Emerging growth company
State of Incorporation
DE
Business Address
2929 N COMMERCE PKWY, MIRAMAR, FL, 33025
Mailing Address
2929 N COMMERCE PKWY, MIRAMAR, FL, 33025
Phone
954-842-2024
Fiscal Year End
1231
EIN
825024477
Financial Overview
FY2025
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 10-K Annual financial report | March 31, 2026 | View on SEC |
| 8-K Current report of material events | March 31, 2026 | View on SEC |
| 8-K Current report of material events | March 17, 2026 | View on SEC |
| DEF 14A Definitive proxy statement | March 13, 2026 | View on SEC |
| 8-K Current report of material events | March 2, 2026 | View on SEC |
| 8-K Current report of material events | February 19, 2026 | View on SEC |
| 424B4 Prospectus for IPO or offering | February 19, 2026 | View on SEC |
| S-1/A IPO registration amendment | February 17, 2026 | View on SEC |
| SCHEDULE 13G Passive beneficial ownership (>5%) | February 17, 2026 | View on SEC |
| 8-K Current report of material events | February 13, 2026 | View on SEC |
Annual Reports
10-K
March 31, 2026
- Proprietary TOBI and TRBC platforms target chronic, age-related diseases.
- Scientific validation in Science Advances confirms HCW9206 improves CAR-T cell function.
Material Events
8-K
Financial Distress
March 31, 2026
High Impact
- Initiation of Phase 1b clinical trial for HCW9302 (alopecia areata) with data expected H1 2026
- Diversified revenue streams through licensing deals and reagent sales
8-K
Financial Distress
March 2, 2026
High Impact
- HCW Biologics successfully regained compliance with Nasdaq listing requirements.
- The immediate threat of delisting has been removed, ensuring continued stock liquidity on Nasdaq.
8-K
Financial Distress
December 31, 2025
High Impact
- HCW Biologics Inc. believes it has successfully resolved a major financial issue that could have led to Nasdaq delisting.
- The company has increased its stockholders' equity to meet Nasdaq's minimum $2.5 million requirement.
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.